Affimed NV (LTS:0HL9) Land And Improvements : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Affimed NV Land And Improvements?

Affimed NV's land and improvements for the quarter that ended in Sep. 2024 was $0.00 Mil.

Affimed NV Land And Improvements Historical Data

The historical data trend for Affimed NV's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affimed NV Land And Improvements Chart

Affimed NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Land And Improvements

Get a 7-Day Free Trial

Affimed NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Land And Improvements	Get a 7-Day Free Trial															-	-	-	-	-

Affimed NV Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Affimed NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (LTS:0HL9) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

AFMD:USA A28A:Germany

Address

Gottlieb-Daimler-Strabe 2, Mannheim, BW, DEU, 68165

Website

https://www.affimed.com

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

Affimed NV Headlines

No Headlines